US Stock MarketDetailed Quotes
RLMD Relmada Therapeutics
- 3.020
- +0.120+4.14%
Close Nov 29 13:00 ET
- 3.000
- -0.020-0.66%
Post 17:02 ET
91.13MMarket Cap-1055P/E (TTM)
3.070High2.776Low111.99KVolume2.890Open2.900Pre Close333.16KTurnover0.41%Turnover RatioLossP/E (Static)30.17MShares7.22352wk High1.91P/B83.17MFloat Cap1.88052wk Low--Dividend TTM27.54MShs Float54.000Historical High--Div YieldTTM10.15%Amplitude1.810Historical Low2.974Avg Price1Lot Size
About Relmada Therapeutics Company
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Company Profile
SymbolRLMD
Company NameRelmada Therapeutics
Listing DateOct 10, 2019
Issue Price0.00
Founded2012
CEODr. Sergio Traversa
MarketNASDAQ
Employees20
Fiscal Year Ends12-31
Address2222 Ponce de Leon Boulevard,3rd floor
CityCoral Gables
ProvinceFlorida
CountryUnited States of America
Zip Code33134
Phone1-786-629-1376
Websitehttp://www.relmada.com
Company Executives
- Name
- Position
- Salary
- Dr. Sergio Traversa
- Chief Executive Officer and Director
- 4.78M
- Maged Shenouda
- Chief Financial Officer and Principal Accounting Officer
- 2.34M
- Charles S. Ence
- Chief Accounting and Compliance Officer
- 2.33M
- Charles J. Casamento
- Chairman of the Board
- 674.90K
- Fabiana Fedeli
- Independent Director
- 1.33M
- Paul Kelly
- Independent Director
- 1.67M
- John Glasspool
- Independent Director
- 604.77K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data